We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?
Read MoreHide Full Article
Key Takeaways
MED shares gained 13.6% in a month as improving operating indicators supported momentum.
Medifast's coach productivity rose 41% year over year, reaching its highest level since Q2 2022.
MED's active earning coach base fell 48.7% year over year, keeping revenue under pressure.
Medifast, Inc. (MED - Free Report) shares have gained 13.6% in the past month compared with the industry's 3.5% growth, bringing the sustainability of that move into focus. The stock's next leg may depend on whether improving operating indicators translate into a firmer business trend.
Image Source: Zacks Investment Research
Coach productivity and earnings expectations are moving in a better direction. Revenue and the size of the active coach base, however, remain under pressure.
MED's 13.5% Monthly Gain Needs Fundamental Support
The recent rally comes against a mixed operating backdrop. Second-quarter 2026 revenues were $76.4 million, down from $105.6 million a year earlier, as fewer active earning coaches continued to weigh on the business.
The sequential picture is steadier. Management said revenues have stabilized around the mid-$70 million level in recent quarters and maintained full-year revenue guidance of $270 million to $300 million. That stability offers some support for the stock's momentum, but a durable recovery still requires improvement in the underlying sales engine.
MED's Earnings Surprise Adds to the Momentum Case
Medifast reported a second-quarter loss of 28 cents per share, substantially narrower than the consensus loss of 67 cents. Revenues also came in slightly above expectations, giving investors a better-than-feared quarterly result even as year-over-year sales remained weak.
Estimate revisions add another constructive signal. The fiscal-year earnings estimate has moved 49.2% higher over the past four weeks. Rising earnings expectations can support price momentum when investors see a better path for profitability, although the company still expects a loss for 2026.
Medifast's Coach Productivity Is Improving
Average revenue per active earning coach increased 41% year over year to $6,529 in the second quarter and rose 20% sequentially. That marked the third consecutive quarter of year-over-year productivity growth and the highest level since the second quarter of 2022.
Management views productivity as an early indicator because stronger coach output has historically preceded better client acquisition, coach growth and revenue expansion. The company expects productivity to continue improving through 2026, helped by its focus on more productive coach organizations and the rollout of Trilivy-related initiatives.
MED Still Faces a Shrinking Coach Base
The main constraint remains the size of Medifast's network. Active earning coaches fell 48.7% year over year to 11,700, and the company expects the count to continue declining during 2026 despite anticipating growth in new coach additions in the second half.
Among consumer-staples peers, Mama's Creations, Inc. (MAMA - Free Report) operates in prepared foods, while US Foods Holding Corp. (USFD - Free Report) is a foodservice distributor. Both offer a broader sector comparison for Medifast, though their operating models differ from MED's coach-led metabolic-health business.
MED's Momentum Score Supports a Mixed Setup
The stock currently carries a Zacks Rank #3 (Hold) and a Momentum Score of A. The favorable Momentum Score indicates that MED screens well on momentum characteristics, which fits with the recent share-price advance. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
The broader Style Score picture is less supportive. MED has a Value Score of D, Growth Score of F and VGM Score of D. Since Style Scores are designed to complement the Zacks Rank, that combination points to a mixed setup rather than an across-the-board positive signal. Continued productivity gains, firmer revenues and progress toward profitability would be important for sustaining the recent momentum.
View the Zacks #1 Rank List
Image: Bigstock
MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?
Key Takeaways
Medifast, Inc. (MED - Free Report) shares have gained 13.6% in the past month compared with the industry's 3.5% growth, bringing the sustainability of that move into focus. The stock's next leg may depend on whether improving operating indicators translate into a firmer business trend.
Image Source: Zacks Investment Research
Coach productivity and earnings expectations are moving in a better direction. Revenue and the size of the active coach base, however, remain under pressure.
MED's 13.5% Monthly Gain Needs Fundamental Support
The recent rally comes against a mixed operating backdrop. Second-quarter 2026 revenues were $76.4 million, down from $105.6 million a year earlier, as fewer active earning coaches continued to weigh on the business.
The sequential picture is steadier. Management said revenues have stabilized around the mid-$70 million level in recent quarters and maintained full-year revenue guidance of $270 million to $300 million. That stability offers some support for the stock's momentum, but a durable recovery still requires improvement in the underlying sales engine.
MED's Earnings Surprise Adds to the Momentum Case
Medifast reported a second-quarter loss of 28 cents per share, substantially narrower than the consensus loss of 67 cents. Revenues also came in slightly above expectations, giving investors a better-than-feared quarterly result even as year-over-year sales remained weak.
MEDIFAST INC Price, Consensus and EPS Surprise
MEDIFAST INC price-consensus-eps-surprise-chart | MEDIFAST INC Quote
Estimate revisions add another constructive signal. The fiscal-year earnings estimate has moved 49.2% higher over the past four weeks. Rising earnings expectations can support price momentum when investors see a better path for profitability, although the company still expects a loss for 2026.
Medifast's Coach Productivity Is Improving
Average revenue per active earning coach increased 41% year over year to $6,529 in the second quarter and rose 20% sequentially. That marked the third consecutive quarter of year-over-year productivity growth and the highest level since the second quarter of 2022.
Management views productivity as an early indicator because stronger coach output has historically preceded better client acquisition, coach growth and revenue expansion. The company expects productivity to continue improving through 2026, helped by its focus on more productive coach organizations and the rollout of Trilivy-related initiatives.
MED Still Faces a Shrinking Coach Base
The main constraint remains the size of Medifast's network. Active earning coaches fell 48.7% year over year to 11,700, and the company expects the count to continue declining during 2026 despite anticipating growth in new coach additions in the second half.
Among consumer-staples peers, Mama's Creations, Inc. (MAMA - Free Report) operates in prepared foods, while US Foods Holding Corp. (USFD - Free Report) is a foodservice distributor. Both offer a broader sector comparison for Medifast, though their operating models differ from MED's coach-led metabolic-health business.
MED's Momentum Score Supports a Mixed Setup
The stock currently carries a Zacks Rank #3 (Hold) and a Momentum Score of A. The favorable Momentum Score indicates that MED screens well on momentum characteristics, which fits with the recent share-price advance. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
The broader Style Score picture is less supportive. MED has a Value Score of D, Growth Score of F and VGM Score of D. Since Style Scores are designed to complement the Zacks Rank, that combination points to a mixed setup rather than an across-the-board positive signal. Continued productivity gains, firmer revenues and progress toward profitability would be important for sustaining the recent momentum.